DKSH Expands into Middle East Healthcare Market with NewBridge Acquisition

DKSH Management Ltd. has agreed to acquire NewBridge Pharmaceuticals, a healthcare commercialization platform specializing in specialty and rare disease medicines in the Middle East and North Africa. This acquisition marks DKSH's entry into the MENA region, aligning with its strategy to expand beyond Asia Pacific. Valued at USD 390 million, the deal aims to enhance DKSH's offerings and strengthen its position in the healthcare sector.

NewBridge, established in 2010 and headquartered in Dubai, operates in 14 markets, including key areas such as Saudi Arabia and the UAE. It offers innovative medicines in fields like oncology and neurology. The company anticipates generating net sales of approximately USD 385 million in 2027, with a high single-digit EBITDA margin.

This acquisition is expected to be financially beneficial for DKSH, contributing to its net sales growth and core EBIT margin. The transaction, subject to regulatory approvals, is anticipated to conclude by Q1 2027.